Articles

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study

Department of Hematology, Zealand University Hospital, Roskilde, Denmark; Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
Department of Hematology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; Biotech Research and Innovation Center, University of Copenhagen, Copenhagen, Denmark
Department of Hematology, Zealand University Hospital, Roskilde, Denmark
Herlev University Hospital, Copenhagen, Denmark
Department of Hematology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; Department of Public Health, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark
Department of Hematology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
Department of Hematology, Zealand University Hospital, Roskilde, Denmark
Department of Hematology, Zealand University Hospital, Roskilde, Denmark; Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
Department of Pathology, Zealand University Hospital, Roskilde, Denmark
Herlev University Hospital, Copenhagen, Denmark
Department of Clinical Genetics, Odense University Hospital, Odense, Denmark
Department of Hematology, Odense University Hospital, Odense, Denmark
Department of Hematology, South-West Jutlandic Hospital, Esbjerg, Denmark
Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
Herlev University Hospital, Copenhagen, Denmark; Department of Laboratory Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA; Data and Development Support, Region Zealand, Sorø, Denmark
Department of Pathology, Zealand University Hospital, Roskilde, Denmark
Department of Clinical Genetics, Odense University Hospital, Odense, Denmark
Department of Hematology, Zealand University Hospital, Roskilde, Denmark
Department of Hematology, Zealand University Hospital, Roskilde, Denmark
Department of Hematology, Zealand University Hospital, Roskilde, Denmark
Vol. 105 No. 9 (2020): September, 2020 https://doi.org/10.3324/haematol.2019.235648